Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -11.97 | 3.20 | 3.63 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 25.13 | 2.12 | 1.70 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -24.68 | 3.04 | 4.04 | |
| Cash | -14.29 | 6.99 | 8.16 | |
| Capex | -1298.12 | < 0.005 | < 0.005 | |
| Free Cash Flow | -76.14 | -1.13 | -0.64 | |
| Revenue | 4.71 | 1.58 | 1.51 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -0.58 | 0.89 | 0.90 | |
| Operating Margin | 33.23 | -0.92 | -1.37 | |
| ROA | 25.31 | -0.13 | -0.17 | |
| ROE | 8.13 | -0.47 | -0.52 | |
| ROIC | 17.09 | -0.21 | -0.26 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of AXSM is permitted for members.
5
Growth
The "Growth Entry" for the Focus of AXSM is permitted for members.
6
Leverage & Liquidity